• Record: found
  • Abstract: found
  • Article: found
Is Open Access

Brexit – What are the potential consequences for pharma patents and SPCs?

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      Brexit raises a number of difficult questions with regard to intellectual property rights in a post-Brexit world, particularly for UK based pharma companies. Whilst the position with regard to the current European patent system is unchanged, the fate of the unitary patent and the unified patent court remains uncertain. Of more immediate concern is the possible future position with respect to supplementary patent certificates. Should the UK fail to reach an agreement with the EU with respect to marketing authorisations for new pharmaceuticals then there is a real possibility that UK based pharma companies may find themselves in a position where they are unable to obtain EU-wide SPC protection.

      Related collections

      Author and article information

      Beck Greener, Fulwood House, 12 Fulwood Place, London WC1V 6HR, United Kingdom
      Author notes
      *Corresponding author. Tel.: +44 20 7693 5600 Fax: +44 20 7693 5601 E-mail: jfraser@

      Conflicts of Interest

      Jamie Fraser is an associate and James Stones is a partner at Beck Greener, a London based firm of Chartered and European Patent and Trademark attorneys.

      British Journal of Pharmacy
      University of Huddersfield Press
      05 September 2017
      : 2
      : 1
      : 75-79
      © 2017, Jamie Fraser, James Stones

      This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0

      Expert Opinion


      Comment on this article